EBS
Price
$7.59
Change
-$0.04 (-0.52%)
Updated
Sep 5, 04:59 PM (EDT)
Capitalization
404.4M
60 days until earnings call
ELAN
Price
$18.43
Change
+$0.96 (+5.50%)
Updated
Sep 5, 04:59 PM (EDT)
Capitalization
9.16B
66 days until earnings call
Interact to see
Advertisement

EBS vs ELAN

Header iconEBS vs ELAN Comparison
Open Charts EBS vs ELANBanner chart's image
Emergent Biosolutions
Price$7.59
Change-$0.04 (-0.52%)
Volume$13.29K
Capitalization404.4M
Elanco Animal Health
Price$18.43
Change+$0.96 (+5.50%)
Volume$51.28K
Capitalization9.16B
EBS vs ELAN Comparison Chart in %
Loading...
EBS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ELAN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
EBS vs. ELAN commentary
Sep 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EBS is a Buy and ELAN is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 06, 2025
Stock price -- (EBS: $7.63 vs. ELAN: $17.47)
Brand notoriety: EBS: Not notable vs. ELAN: Notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: EBS: 70% vs. ELAN: 95%
Market capitalization -- EBS: $404.4M vs. ELAN: $9.16B
EBS [@Pharmaceuticals: Generic] is valued at $404.4M. ELAN’s [@Pharmaceuticals: Generic] market capitalization is $9.16B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $67.95B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.88B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EBS’s FA Score shows that 1 FA rating(s) are green whileELAN’s FA Score has 0 green FA rating(s).

  • EBS’s FA Score: 1 green, 4 red.
  • ELAN’s FA Score: 0 green, 5 red.
According to our system of comparison, EBS is a better buy in the long-term than ELAN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EBS’s TA Score shows that 7 TA indicator(s) are bullish while ELAN’s TA Score has 5 bullish TA indicator(s).

  • EBS’s TA Score: 7 bullish, 4 bearish.
  • ELAN’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, EBS is a better buy in the short-term than ELAN.

Price Growth

EBS (@Pharmaceuticals: Generic) experienced а -9.06% price change this week, while ELAN (@Pharmaceuticals: Generic) price change was -5.31% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -0.80%. For the same industry, the average monthly price growth was +10.12%, and the average quarterly price growth was +85.54%.

Reported Earning Dates

EBS is expected to report earnings on Nov 05, 2025.

ELAN is expected to report earnings on Nov 11, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (-0.80% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ELAN($9.16B) has a higher market cap than EBS($404M). ELAN has higher P/E ratio than EBS: ELAN (20.94) vs EBS (2.89). ELAN YTD gains are higher at: 44.261 vs. EBS (-20.188). ELAN has higher annual earnings (EBITDA): 1.45B vs. EBS (344M). ELAN has more cash in the bank: 539M vs. EBS (267M). EBS has less debt than ELAN: EBS (668M) vs ELAN (4.21B). ELAN has higher revenues than EBS: ELAN (4.48B) vs EBS (812M).
EBSELANEBS / ELAN
Capitalization404M9.16B4%
EBITDA344M1.45B24%
Gain YTD-20.18844.261-46%
P/E Ratio2.8920.9414%
Revenue812M4.48B18%
Total Cash267M539M50%
Total Debt668M4.21B16%
FUNDAMENTALS RATINGS
EBS vs ELAN: Fundamental Ratings
EBS
ELAN
OUTLOOK RATING
1..100
7056
VALUATION
overvalued / fair valued / undervalued
1..100
54
Fair valued
93
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
3279
PRICE GROWTH RATING
1..100
3939
P/E GROWTH RATING
1..100
6493
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EBS's Valuation (54) in the Biotechnology industry is somewhat better than the same rating for ELAN (93) in the Agricultural Commodities Or Milling industry. This means that EBS’s stock grew somewhat faster than ELAN’s over the last 12 months.

EBS's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ELAN (100) in the Agricultural Commodities Or Milling industry. This means that EBS’s stock grew similarly to ELAN’s over the last 12 months.

EBS's SMR Rating (32) in the Biotechnology industry is somewhat better than the same rating for ELAN (79) in the Agricultural Commodities Or Milling industry. This means that EBS’s stock grew somewhat faster than ELAN’s over the last 12 months.

EBS's Price Growth Rating (39) in the Biotechnology industry is in the same range as ELAN (39) in the Agricultural Commodities Or Milling industry. This means that EBS’s stock grew similarly to ELAN’s over the last 12 months.

EBS's P/E Growth Rating (64) in the Biotechnology industry is in the same range as ELAN (93) in the Agricultural Commodities Or Milling industry. This means that EBS’s stock grew similarly to ELAN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EBSELAN
RSI
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
74%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
63%
Momentum
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 2 days ago
55%
MACD
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
79%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
75%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
65%
Advances
ODDS (%)
Bullish Trend 16 days ago
76%
Bullish Trend 10 days ago
62%
Declines
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 3 days ago
74%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
71%
Aroon
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
70%
View a ticker or compare two or three
Interact to see
Advertisement
EBS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ELAN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PCSGX15.240.17
+1.13%
PACE Small/Medium Co Growth Equity P
VESMX19.800.19
+0.97%
VELA Small Cap I
SMYIX27.920.25
+0.90%
Franklin Global Equity I
WFINX59.150.50
+0.85%
Allspring Index C
RDCEX15.300.09
+0.59%
Columbia Disciplined Core C

EBS and

Correlation & Price change

A.I.dvisor indicates that over the last year, EBS has been loosely correlated with SIGA. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if EBS jumps, then SIGA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EBS
1D Price
Change %
EBS100%
-2.55%
SIGA - EBS
43%
Loosely correlated
-1.39%
VTRS - EBS
42%
Loosely correlated
-2.09%
ELAN - EBS
39%
Loosely correlated
+0.69%
HKMPF - EBS
34%
Loosely correlated
N/A
PAHC - EBS
34%
Loosely correlated
+2.29%
More

ELAN and

Correlation & Price change

A.I.dvisor indicates that over the last year, ELAN has been loosely correlated with VTRS. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if ELAN jumps, then VTRS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ELAN
1D Price
Change %
ELAN100%
+0.69%
VTRS - ELAN
54%
Loosely correlated
-2.09%
ZTS - ELAN
46%
Loosely correlated
+0.51%
EBS - ELAN
39%
Loosely correlated
-2.55%
PAHC - ELAN
37%
Loosely correlated
+2.29%
TLRY - ELAN
35%
Loosely correlated
-2.95%
More